Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16505653 | 1.00 | MAP3K14 (0.33) | MAP3K14PRKD1PIK3CG | |
| SCHEMBL16532260 | 0.80 | MAP3K14 (0.37) | MAP3K14PRKD1PIK3CG | |
| SCHEMBL16547152 | 0.80 | MAP3K14 (0.37) | MAP3K14PRKD1PIK3CG | |
| SCHEMBL16522729 | 0.80 | MAP3K14 (0.37) | MAP3K14PRKD1PIK3CG | |
| SCHEMBL16526430 | 0.80 | MAP3K14 (0.37) | MAP3K14PRKD1PIK3CG | |
| SCHEMBL13561292 | 0.78 | PIK3CG (0.40) | PIK3CG | |
| SCHEMBL18888152 | 0.76 | MAP3K14 (0.39) | MAP3K14PRKD1 | |
| SCHEMBL11915955 | 0.73 | PIK3CG (0.43) | PIK3CG | |
| SCHEMBL16505509 | 0.73 | MAP3K14 (0.32) | MAP3K14 | |
| SCHEMBL22715881 | 0.73 | MAP3K14 (0.32) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9034866-B2 | Tricyclic compounds and methods of use therefor | GENENTECH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2814830-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120980-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | MAP3K14 1050/4885PRKD1 1118/4885PIK3CG 1824/4885 |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | MAP3K14 1050/4885PRKD1 1118/4885PIK3CG 1824/4885 |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885PRKD1 286/4885PIK3CG 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.